Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study

Autor: Meneghini, L. F., Rosenberg, K. H., Koenen, C., Merilainen, M. J., Lüddeke, H.-J.
Předmět:
Zdroj: Diabetes, Obesity & Metabolism; May2007, Vol. 9 Issue 3, p418-427, 10p, 1 Diagram, 5 Charts, 3 Graphs
Abstrakt: Aim: The Predictable Results and Experience in Diabetes through Intensification and Control to Target: An International Variability Evaluation (PREDICTIVE) Study is a large, multi-centre, observational study assessing the safety and efficacy of insulin detemir in everyday clinical practice. Methods: This subgroup analysis of the German cohort of PREDICTIVE evaluates over 3 months, patients with type 2 diabetes who were transferred to insulin detemir ± oral antidiabetic drugs (OADs) from an OAD-only regimen (n = 1321), NPH insulin ± OADs (n = 251) or insulin glargine ± OADs (n = 260). Results: Among all groups, 3 months after starting treatment with insulin detemir, total, daytime and nocturnal hypoglycaemic events/patient were reduced by 84, 80 and 90%, respectively, from baseline. No major hypoglycaemic events were reported during treatment with insulin detemir. HbAlc was significantly reduced from baseline in each of the subgroups (−1.29,−0.60 and−0.59% for patients previously taking OADs only, NPH insulin ± OADs and insulin glargine ± OADs respectively; p < 0.0001), as was fasting blood glucose (FBG) (−58.1,−29.1 and−24.6 mg/dl; p < 0.0001) and FBG variability−8.2 mg/dl,−5.7 mg/dl; p < 0.0001 and −5.1 mg/dl; p = 0.0008). All subgroups combined lost an average of 0.9 kg of body weight (p < 0.0001) during the study. Total daily basal insulin dose increased slightly from baseline for those patients on a prior insulin regimen, and in this study 79% of patients used insulin detemir once daily. Conclusions: These data confirm the short-term safety and efficacy of insulin detemir ± OADs in a real-world scenario and support the findings of randomized controlled clinical trials with insulin detemir, including its limited effects on body weight. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz: